DnB Asset Management
RVNC

DnB Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

DnB Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,229
Closed -$155K – 732
2024
Q2 		$155K Buy
60,229
+12,201
+25% +$41.7K ﹤0.01% 698
2024
Q1 		$236K Buy
48,028
+13,376
+39% +$79.2K ﹤0.01% 687
2023
Q4 		$305K Buy
34,652
+10,706
+45% +$87.7K ﹤0.01% 642
2023
Q3 		$275K Buy
23,946
+2,171
+10% +$41.7K ﹤0.01% 654
2023
Q2 		$551K Buy
21,775
+7,410
+52% +$231K ﹤0.01% 631
2023
Q1 		$462K Buy
14,365
+2,574
+22% +$80.2K ﹤0.01% 631
2022
Q4 		$218K Buy
+11,791
New +$270K ﹤0.01% 635

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

DnB Asset Management's RVNC Position: Q3 2024 in Review

DnB Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 60,229 shares — an estimated $155K sold.

DnB Asset Management first reported a position in RVNC in Q4 2022 and held it in 7 quarters. The position peaked at $551K in Q2 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • DnB Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • DnB Asset Management sold 60,229 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $155K.
  • DnB Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 7 quarters.
  • DnB Asset Management's Revance Therapeutics, Inc. position peaked at $551K in Q2 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on DnB Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.